Skip to content

The Impact of SCN9A Gene Polymorphism on Individual Pain Perception in the General Population

The Impact of SCN9A Gene Polymorphism on Individual Pain Perception in the General Population

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01507493
Enrollment
200
Registered
2012-01-11
Start date
2011-01-31
Completion date
2012-12-31
Last updated
2014-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Surgery

Keywords

gene polymorphism, SCN9A, pain perception, postoperative pain

Brief summary

This study was conducted to explore whether the non-synonymous single-nucleotide polymorphisms in SCN9A gene can predict individual basal pain perception and postoperative pain intensity in the general population undergoing upper abdominal surgery. Methods: Patients receiving elective upper abdominal surgery under general anesthesia were recruited into this study. Genotyping of SCN9A was carried out by direct sequencing. The investigators measured their preoperative pressure pain threshold (PPT) and pressure pain tolerance (PTO). The visual analog scale (VAS) was used for pain evaluation at rest during patient-controlled analgesia (PCA) treatment 0 h, 12 h ,24 h and 48h after operation. And the PCA press frequency and drug consumption were recorded.

Detailed description

Patients with the following diseases were excluded: known history of chronic pain, psychiatric diseases or communication disorders, diabetes mellitus, severe cardiovascular diseases, kidney or liver diseases with poor hepatic function, alcohol or drug abuse, heavy smoker, pregnancy or at the lactation period.

Interventions

None listed

Sponsors

Xianwei Zhang
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Aged 20-70 years * Receiving elective upper abdominal surgery * Anesthesiologists (ASA) physical status I or II * Received PCA administration * Agreed to participate the research

Exclusion criteria

* History of chronic pain * Psychiatric diseases * Diabetes mellitus * Severe cardiovascular diseases * Kidney or liver diseases * Alcohol or drug abuse * Heavy smoker * Pregnancy or at lactation period * Refused PCA administration * Disagree to participate to the research

Design outcomes

Primary

MeasureTime frame
Opioid Consumption Dose 48h After Operation.48 hours after the operation
PCA Press Frequency 48h After Operation.48 hours after the operation

Secondary

MeasureTime frameDescription
The Visual Analog Scale 48h After Operation.48 hours after the operationThe visual analog scale (VAS) is used for pain evaluation at rest during patient-controlled analgesia (PCA) treatment 48h after operation. And the visual analog scale is from 0 to 10 which 0 represent no pain while 10 represent unbearable pain
Preoperative Pressure Pain Threshold (PPT)12 hours before the operationThe probe of pressure algometer was positioned perpendicularly to the skin surface of the patient, and the investigator applied continuous pressure at approximately the same rate according to the visual LCD display on the algometer. subjects were asked to say pain when they started to feel pain during the stimulation. The value from the LCD was recorded as the pressure pain threshold.
Preoperative Pressure Pain Tolerance (PTO)12 hours before the operationThe probe of pressure algometer was positioned perpendicularly to the skin surface of the patient, and the investigator applied continuous pressure at approximately the same rate according to the visual LCD display on the algometer. subjects were asked to say ok when they started to feel the pain became intolerable during the stimulation. The value from the LCD was recorded as the pressure pain tolerance.

Countries

China

Participant flow

Participants by arm

ArmCount
Mutant Alleles
grouped by SCN9A mutant alleles including 3312T, 1719R, 1150W.
22
Wild-type Alleles
grouped by SCN9A wild-type alleles including 3312G, 1719C, 1150R.
178
Total200

Baseline characteristics

CharacteristicWild-type AllelesMutant AllelesTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
16 Participants0 Participants16 Participants
Age, Categorical
Between 18 and 65 years
162 Participants22 Participants184 Participants
Age, Continuous55.6 years
STANDARD_DEVIATION 5.3
51.9 years
STANDARD_DEVIATION 9.3
55.2 years
STANDARD_DEVIATION 5.7
Region of Enrollment
China
178 participants22 participants200 participants
Sex: Female, Male
Female
101 Participants12 Participants113 Participants
Sex: Female, Male
Male
77 Participants10 Participants87 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 220 / 178
serious
Total, serious adverse events
0 / 220 / 178

Outcome results

Primary

Opioid Consumption Dose 48h After Operation.

Time frame: 48 hours after the operation

ArmMeasureValue (MEAN)Dispersion
Mutant AllelesOpioid Consumption Dose 48h After Operation.37.4 microgrammeStandard Deviation 10.4
Wild-type AllelesOpioid Consumption Dose 48h After Operation.50.4 microgrammeStandard Deviation 20.4
Primary

PCA Press Frequency 48h After Operation.

Time frame: 48 hours after the operation

ArmMeasureValue (MEAN)Dispersion
Mutant AllelesPCA Press Frequency 48h After Operation.8.8 presses per dayStandard Deviation 5.6
Wild-type AllelesPCA Press Frequency 48h After Operation.19.9 presses per dayStandard Deviation 12.7
Secondary

Preoperative Pressure Pain Threshold (PPT)

The probe of pressure algometer was positioned perpendicularly to the skin surface of the patient, and the investigator applied continuous pressure at approximately the same rate according to the visual LCD display on the algometer. subjects were asked to say pain when they started to feel pain during the stimulation. The value from the LCD was recorded as the pressure pain threshold.

Time frame: 12 hours before the operation

ArmMeasureValue (MEAN)Dispersion
Mutant AllelesPreoperative Pressure Pain Threshold (PPT)3.6 kg/cm2Standard Deviation 1
Wild-type AllelesPreoperative Pressure Pain Threshold (PPT)3.7 kg/cm2Standard Deviation 1.8
Secondary

Preoperative Pressure Pain Tolerance (PTO)

The probe of pressure algometer was positioned perpendicularly to the skin surface of the patient, and the investigator applied continuous pressure at approximately the same rate according to the visual LCD display on the algometer. subjects were asked to say ok when they started to feel the pain became intolerable during the stimulation. The value from the LCD was recorded as the pressure pain tolerance.

Time frame: 12 hours before the operation

ArmMeasureValue (MEAN)Dispersion
Mutant AllelesPreoperative Pressure Pain Tolerance (PTO)6.6 kg/cm2Standard Deviation 3.6
Wild-type AllelesPreoperative Pressure Pain Tolerance (PTO)6.5 kg/cm2Standard Deviation 2.6
Secondary

The Visual Analog Scale 48h After Operation.

The visual analog scale (VAS) is used for pain evaluation at rest during patient-controlled analgesia (PCA) treatment 48h after operation. And the visual analog scale is from 0 to 10 which 0 represent no pain while 10 represent unbearable pain

Time frame: 48 hours after the operation

ArmMeasureValue (MEAN)Dispersion
Mutant AllelesThe Visual Analog Scale 48h After Operation.6.9 units on a scaleStandard Deviation 2.5
Wild-type AllelesThe Visual Analog Scale 48h After Operation.5.0 units on a scaleStandard Deviation 1.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026